HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Compare relative returns, fundamentals, and sector rankings head-to-head.

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Foghorn Therapeutics, Inc.

Contributing Author

Recent Articles by Foghorn Therapeutics, Inc.

May-12
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May FHTX GlobeNewswire
May-07
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update FHTX -10.26% GlobeNewswire
Apr-21
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting FHTX GlobeNewswire
Apr-09
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting FHTX GlobeNewswire
Mar-11
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook FHTX -12.92% FHTX GlobeNewswire
Feb-24
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences FHTX GlobeNewswire
Feb-23
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer FHTX GlobeNewswire
Feb-03
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit FHTX GlobeNewswire
Jan-13
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium FHTX -5.54% FHTX GlobeNewswire
Jan-09
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 FHTX GlobeNewswire
Nov-25
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference FHTX GlobeNewswire
Nov-05
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update FHTX +13.31% GlobeNewswire
Nov-03
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences FHTX GlobeNewswire
Oct-30
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs FHTX GlobeNewswire
Oct-16
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit FHTX GlobeNewswire
Aug-27
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences FHTX GlobeNewswire
Aug-05
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update FHTX GlobeNewswire
May-22
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences FHTX GlobeNewswire
May-14
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update FHTX -5.08% GlobeNewswire
May-05
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference FHTX -8.49% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)